Treatment of Focal Seizures: Clinical Practice Guideline Recommendations
For newly diagnosed focal seizures in adults, lamotrigine or levetiracetam should be first-line treatment, with carbamazepine as an alternative option; for children, the same agents apply with carbamazepine, lamotrigine, or levetiracetam all being appropriate first-line choices.
Adults with Focal Seizures
First-Line Treatment Options
The evidence strongly supports three primary options for adults with newly diagnosed focal epilepsy 1, 2:
Lamotrigine: Demonstrates the best overall profile for treatment failure rates and tolerability. High-certainty evidence shows lamotrigine performs better than most other treatments including carbamazepine (HR 1.26,95% CI 1.10-1.44 for treatment failure) 1.
Levetiracetam: Shows equivalent efficacy to lamotrigine with no significant differences in treatment failure outcomes (HR 1.01,95% CI 0.88-1.20 comparing lamotrigine vs levetiracetam) 1. Both agents perform better than all other antiseizure medications.
Carbamazepine: Remains a viable first-line option despite slightly higher treatment failure rates compared to lamotrigine. It is the most cost-effective option when considering long-term treatment costs 3.
Dosing Strategies for Adults
While specific loading doses are not standardized in outpatient settings for newly diagnosed epilepsy, the evidence supports:
- Monotherapy initiation: Start with a single agent and titrate to effective dose before considering alternatives 2
- Avoid polytherapy initially: Multiple medications should not be used as first-line treatment 1
Special Considerations for Elderly (≥60 years)
For older adults, lamotrigine should be preferred over carbamazepine due to fewer drug interactions 4. Gabapentin may also be considered in this population 2.
Children with Focal Seizures
First-Line Treatment Options
For pediatric patients with focal seizures 4, 1:
- Carbamazepine, lamotrigine, or levetiracetam are all recommended as first-line agents (ILAE level A-C evidence)
- Oxcarbazepine is an alternative, though its level A evidence comes from a single trial where poor phenytoin tolerability may have influenced results 4
Important Caveat for Neonates
This is a completely different population with distinct guidelines. For neonatal seizures (not the same as childhood focal epilepsy), phenobarbital is the first-line treatment, not the agents listed above 5. Phenobarbital at 20 mg/kg loading dose showed 80% seizure control in neonates 5. Second-line options for neonates include phenytoin or levetiracetam 5.
Alternative and Second-Tier Options
If first-line treatments fail or are not tolerated 4, 1:
- Eslicarbazepine acetate
- Lacosamide (oral only for pediatric use ≥4 years)
- Zonisamide
- Gabapentin (particularly for elderly)
These agents have ILAE level A evidence for adults but are generally reserved for situations where first-line treatments are inadequate 2.
Agents to Avoid or Use with Caution
- Phenytoin and phenobarbitone: While effective for seizure control, they have significantly higher treatment failure rates due to adverse effects (HR 1.44 and 1.97 respectively compared to lamotrigine) 1
- Topiramate and gabapentin: Show higher treatment failure rates compared to lamotrigine and levetiracetam 1
Key Clinical Pitfalls
Do not routinely prescribe antiseizure medications after a first unprovoked seizure 6. Treatment should begin after diagnosis of epilepsy (typically requiring two or more unprovoked seizures).
Avoid valproic acid in women of childbearing potential unless no other suitable alternatives exist, due to teratogenic risks 6, 4, 7. When used, folic acid supplementation is mandatory 6.
Do not use polytherapy as initial treatment. The evidence consistently supports monotherapy as the appropriate starting approach 1, 2.
Treatment Discontinuation
After 2 seizure-free years, discontinuation of antiseizure medication should be considered, with the decision made in consultation with the patient and family regarding clinical, social, and personal factors 6.
Emergency Department Context
For patients with known seizure disorders presenting to the ED, there is insufficient evidence to support one route of administration (oral vs. parenteral) over another for preventing early recurrent seizures 8. The choice is at the physician's discretion, though loading doses are commonly performed despite lack of strong supporting evidence 8.